Burning Rock Announces Founder’s Purchase of Its ADSs

Core Viewpoint - Burning Rock Biotech Limited's founder and CEO, Mr. Yusheng Han, has demonstrated confidence in the company's future by purchasing approximately US$811,721.28 worth of the company's American Depositary Shares (ADSs) from the open market [1]. Group 1: Company Actions - Mr. Han's purchase of the company's ADSs was conducted in compliance with applicable rules and regulations, as well as the company's insider trading policy [1]. - There is potential for Mr. Han to continue purchasing the company's ADSs through various means, including open-market transactions and block trades, depending on market conditions [2]. Group 2: Company Overview - Burning Rock Biotech Limited focuses on the application of next generation sequencing (NGS) technology in precision oncology, with a mission to guard life via science [3]. - The company's business includes NGS-based therapy selection testing for late-stage cancer patients and cancer early detection, which has progressed to the clinical validation stage [3].